|Chemical and physical data|
|Molar mass||295.34 g/mol g·mol−1|
|3D model (JSmol)|
GYKI-52895 is a drug which is a 2,3-benzodiazepine derivative. Unlike other similar drugs, GYKI-52895 is a selective dopamine reuptake inhibitor, which presumably would produce stimulant effects in vivo.[original research?] Its DRI activity is shared by numerous addictive drugs including amphetamine and its derivatives (e.g. dextromethamphetamine), cocaine, and methylphenidate and its derivatives (e.g. ethylphenidate). However, dopaminergic drugs are also prone to producing emetic effects such as in the case of apomorphine.
* atypical activity profile (not GABAA receptor ligands)
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|